Medical Necessity Assessment for Rituximab in Subglottic Stenosis

Diagnosis and Treatment Guidelines

• The American College of Rheumatology/Vasculitis Foundation guidelines recommend immunosuppressive therapy for patients with GPA and actively inflamed subglottic stenosis, but this patient lacks confirmed ANCA-associated vasculitis 1, 2, 3
• The American College of Rheumatology/Vasculitis Foundation guidelines suggest that immunosuppressive therapy comprises glucocorticoids and other agents, with the degree of therapy based on severity of other disease manifestations 1, 2
• Surgical dilation with intralesional glucocorticoid injection is recommended for stenoses that are longstanding, fibrotic, or unresponsive to immunosuppression 1, 2

Risk-Benefit Analysis

• Rituximab carries significant risks, including severe infectious complications and progressive multifocal leukoencephalopathy, particularly in immunosuppressed patients 4, 5
• The patient lacks confirmed systemic vasculitis or severe autoimmune disease that would justify the risks of rituximab 1, 2, 3

Treatment Recommendations

• The standard of care for this patient should prioritize continued endoscopic management with serial dilations and intralesional corticosteroid injections as needed 1, 2